Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Hepatitis

San Diego's Unhoused Population Faces Simultaneous Hepatitis A and Mpox Threats — Health Officials Urgently Expanding Vaccination Access

San Diego health officials are escalating vaccination efforts as hepatitis A and mpox cases rise simultaneously among the city's large unhoused population. Officials report cases in downtown encampments.

Medical Daily

FDA Warns New Yorkers: Hepatitis A Linked to Frozen Blood Clams Sold in New York State — Illnesses Span Months

The FDA issued a public alert about hepatitis A-linked blood clams distributed in New York. Cases traced to La Serranita frozen blood clams imported from Ecuador. First illness reported in July 2025.

Medical Daily

The U.S. Was on Track to Eliminate Hepatitis C by 2030 — Then Came the Federal Public Health Cuts That Are Dismantling the Programs Doing It

Federal public health cuts are jeopardizing hepatitis C elimination programs in California, putting testing and curative treatment access at risk.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead

Assembly Biosciences (NASDAQ:ASMB) outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming decisions tied to its herpes simplex virus type 2 program, expansion of its hepatitis delta candidate

MarketBeat

Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands

Assembly Biosciences (NASDAQ:ASMB) is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indications, Chief Executive Officer Jason Okazaki said during a Jefferies biotech event. Okazaki said 2024 w

MarketBeat

What killed Beethoven? His own DNA finally answered after 200 years, with a bombshell twist

A groundbreaking genetic study has provided new insights into the life and death of composer Ludwig van Beethoven nearly 200 years after his passing. Researchers analyzed DNA from authenticated hair samples and found evidence of inherited liver disease risk factors and a hepatitis B infection that may have contributed to…

The Economic Times

First-in-Class Hepatitis B Drug Shows Promise for 'Functional Cure' in Early Trials

An experimental new treatment for chronic hepatitis B is raising hopes for what researchers call a potential "functional cure," a milestone that could change how the viral liver disease is managed in the future.

Medical Daily

Read news from The Economist, FT, and more,
with one subscription

Experimental hepatitis B drug may offer 'functional cure' for some patients

New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus

AAP

GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies

GSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achieving a functional cure after six months of treatment. This offers a potential finite treatment course, a significant advancement over lifelong antiviral pills for the over 250 million people globally living with…

The Economic Times

Experimental hepatitis B drug might offer 'functional cure' for a subset of patients

New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus

AAP

FDA fast-tracks promising hepatitis B drug after ‘remarkable’ trial results

New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the dangerous liver virus

The Independent UK

Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance

Mirum Pharmaceuticals (NASDAQ:MIRM) executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and additional business development activity expanding its portfolio. Speaking at RBC Capital Markets’ 20

MarketBeat

How a remarkable trial on bedrest during the Korean war helped lead to evidence-based medicine

In 1959, a young doctor named David Sackett stumbled on a clinical trial that would change his life – and most of ours. The study showed that conventional wisdom on bed rest in medicine was wrong. And it helped lead Sackett and others to develop evidence-based medicine, in which doctors…

The Conversation

Burnham criticises Government over ‘dividing lines’ in blood scandal payouts

A memorial service for those affected was held at St Paul’s Cathedral in London, with Prime Minister Sir Keir Starmer attending.

Evening Standard

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

UK must ‘always remember’ those affected by infected blood scandal

A memorial service for those affected was held at St Paul’s Cathedral in London.

Roll Call

US overlooks drug treatment centers in hepatitis C fight

MANCHESTER and LONDON, England — Alison Starkie spends her days tracking down people who need testing or treatment for hepatitis C, especially those who are unhoused or actively using drugs. Starkie, an intervention worker for a drug treatment service, recalled the difficulty of treating a man living in a tent…

MarketBeat

Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference

Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing programs in herpes simplex virus, hepatitis D and transplant-related herpes viruses. Gaggar describe

The Guardian - AU

Health alert issued urging thousands of patients of retired Sydney dentist to get tested for HIV and hepatitis

Health official says thousands of people may be affected due to ‘poor infection control practices’ at Strathfield clinic

Get all your
news in one place.

100's of premium titles.
One news app.

AAP

Thousands face tests over dentist HIV, hepatitis risks

A retired dentist who treated thousands of patients over decades may have exposed them to serious bloodborne viruses such as HIV through poor infection control.

MarketBeat

Atea Pharmaceuticals Q1 Earnings Call Highlights

Atea Pharmaceuticals (NASDAQ:AVIR) said it remains on track for two key Phase 3 hepatitis C readouts in 2026 while advancing a newer hepatitis E program aimed at immunocompromised patients with no approved treatment options. During the company’s first-quarter 2026 earnings call, Chief Executive Off

The Times of India

Parents in South Wales urged to reinforce handwash hygiene after hepatitis A outbreak

In light of a hepatitis A outbreak in Barry, Welsh health officials are calling on parents to emphasize the importance of hand hygiene. With three households reporting cases of the illness, there are rising fears of further spread in the community. To combat this, vaccinations are being provided for individuals…

The Guardian - UK

Parents in Wales urged to ‘be vigilant’ about hand-washing amid hepatitis A outbreak

At least three households in Barry, south Wales, identified as having contracted the liver infection

The Independent UK

Hepatitis A outbreak in Welsh seaside town as health officials issue urgent plea to parents

There has been a hepatitis A outbreak in a seaside town in South Wales

Evening Standard

Parents urged to act after hepatitis A outbreak in seaside town

Hepatitis A cases of the same strain have been identified in three separate households in Barry, South Wales.

The Guardian - US

Who is Nicole Saphier, Trump’s new nominee for US surgeon general?

Trump’s third pick for role is a radiologist and Fox News medical contributor who experts say is ‘almost a lock’

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.